title: Impact of coffee on liver diseases: a systematic review.
abstract: Coffee is one of the most commonly consumed beverages in the world. Its health benefits including improved overall survival have been demonstrated in a variety of disease states. To examine the association of coffee consumption with liver disease, a systematic review of studies on the effects of coffee on liver associated laboratory tests, viral hepatitis, nonalcoholic fatty liver disease (NAFLD), cirrhosis and hepatocellular carcinoma (HCC) was performed. Coffee consumption was associated with improved serum gamma glutamyltransferase, aspartate aminotransferase and alanine aminotransferase values in a dose dependent manner in individuals at risk for liver disease. In chronic liver disease patients who consume coffee, a decreased risk of progression to cirrhosis, a lowered mortality rate in cirrhosis patients, and a lowered rate of HCC development were observed. In chronic hepatitis C patients, coffee was associated with improved virologic responses to antiviral therapy. Moreover, coffee consumption was inversely related to the severity of steatohepatitis in patients with non-alcoholic fatty liver disease. Therefore, in patients with chronic liver disease, daily coffee consumption should be encouraged.
authors.affiliation: Department of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA; Department of Surgery, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, CA, USA.
authors.forename: Sammy
authors.initials: S
authors.lastname: Saab
authors.forename: Divya
authors.initials: D
authors.lastname: Mallam
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Cox
authors.forename: Myron J
authors.initials: MJ
authors.lastname: Tong
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D000998:Antiviral Agents; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002110:Caffeine / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000503:physiopathology*; D006521:Hepatitis, Chronic / Q000503:physiopathology*; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000517:prevention & control*; D065626:Non-alcoholic Fatty Liver Disease; D005723:gamma-Glutamyltransferase / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D002110:Caffeine; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
keywords: coffee; liver disease